NCT06801119View on ClinicalTrials.gov

Efficacy and Safety of HN2301 in Refractory Systemic Lupus Erythematosus (SLE)

NARecruitingINTERVENTIONAL
Enrollment

9

Participants

Timeline

Start Date

March 16, 2025

Primary Completion Date

December 31, 2025

Study Completion Date

March 31, 2026

Conditions
Systemic Lupus Erythematosus
Interventions
DRUG

HN2301 injection

Three dose groups were set up, starting from the low dose group and climbing to explore the safe and effective dose.

Trial Locations (2)

Unknown

NOT_YET_RECRUITING

The First Affiliated Hospital of University of Science and Technology of China, Hefei

RECRUITING

The First Affiliated Hospital of University of Science and Technology of China, Hefei

All Listed Sponsors
collaborator

The First Affiliated Hospital of University of Science and Technology of China

OTHER

lead

Shenzhen MagicRNA Biotechnology Co., Ltd

INDUSTRY